Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial

Overview of attention for article published in The Lancet Respiratory Medicine, November 2018

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (94th percentile)
Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

news: 2 news outlets
twitter: 8 X users

facebook: 1 Facebook page
guideline: 5 clinical guideline sources

Readers on

mendeley: 267 Mendeley

So far, Altmetric has seen 8 X posts from 8 X users, with an upper bound of 11,032 followers.

Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. https://t.co/nQA93XkQcO

El uso de Benralizumab (Ac monoclonal citolítico directo vs r. IL-5 alfa) ha demostrado seguridad y eficiencia en pacientes con asma severa y descontrolada tras 2 años de seguimiento en un estudio aleatorizado doble ciego. Estudio BORA en su fase 3. http…

RT @LancetRespirMed: Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled #asthma: 1-year results from the B…

RT @rocioneumo: Extension del estudio BORA: se mantienen los datos de eficacia y seguridad de benralizumab a 2 años de tratamiento en #asma…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 4 additional X posts.